Stomach cancer surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]

Stomach cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stomach Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy and Biopsy

Chest X Ray

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stomach cancer surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stomach cancer surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stomach cancer surgery

CDC on Stomach cancer surgery

Stomach cancer surgery in the news

Blogs on Stomach cancer surgery

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Stomach cancer surgery

## Overview

[edit | edit source]

Surgery is the mainstay of treatment for stomach cancer. Endoscopic resection is suggested for early gastric cancer. There are criteria for endoscopic resection of ealry gastric cancer. Methods for endoscopic resection include endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). Side effects of endoscopy includes bleeding and perforation. For T1 tumors, a 2cm macroscopic resection of tumor margin should be performed. Proximal margin of at least 3 cm is recommended for T2 or deeper tumors with an expansive growth pattern and 5 cm for those with an infiltrative growth pattern. For tumors invading the esophagus, a 5-cm margin is not necessarily required, but frozen section examination of the resection line is desirable to ensure a R0 resection. There is a debate about optimal lymph node removal. D1 lymphadenectomy refers to a dissection of only the perigastric lymph nodes. D2 lymphadenectomy is an extended lymph node dissection, includes removal of nodes along the hepatic, left gastric, celiac, and splenic arteries, as well as those in the splenic hilum. D3 dissection is a super-extended lymphadenectomy. The surgery includes D2 lymphadenectomy plus the removal of nodes within the porta hepatis and periaortic regions.

## Surgical Management Of Early Gastric Cancer

[edit | edit source]

* Early gastric cancer is an invasive gastric cancer that invades no more than the submucosa whatever the lymph node metastasis condition (T1 and any N)
* Endoscopic resection is suggested for:
* Patients without suspected lymph node involvement
* Tumor size <20 mm in diameter
* Differentiated intestinal histology
* In most trials, there are no differences in outcome between the surgical and the endoscopic treatment.[1]

### Standard criteria for endoscopic resection:

[edit | edit source]

The standard criteria for lesions qualifying for endoscopic resection are the following:[2][3]

1) Confined to the mucosa

2) Smaller than 2 cm for superficially elevated type lesions

3) Smaller than 1 cm for the flat and depressed type lesions

4) No ulcer or ulcer scar

5) No venous or lymphatic involvement

Expansion of the criteria to involve more tumors eligible for endoscopic resection was suggested by Japanese centers and these criteria include:[4]

* Differentiated type without ulceration, and mucosal tumors of any size
* Differentiated type, with ulceration, and mucosal tumors less than 30 mm
* Undifferentiated type, without ulceration, and mucosal tumors 20 mm in size or smaller

### Methods of endoscopic resection

[edit | edit source]

The following are the different types of endoscopic resection techniques for gastric cancer:[5]

* Endoscopic mucosal resection (EMR):
* The lesion and the surrounding mucosa are lifted by submucosal injection of saline and removed using a steel snare.

* Endoscopic submucosal dissection (ESD):
* The mucosa surrounding the lesion is incised using a high-frequency electric knife.
* ESD is more likely to result in complete resection of early gastric cancer but requires more time and endoscopic skills.

### Side effects and complications:

[edit | edit source]

###### Bleeding

[edit | edit source]

* Bleeding[6]
* A tumor size of more than 4 cm is a risk factor for acute bleeding
* Antithrombotic drug therapy is a risk factor for delayed bleeding
* Bleeding treatment is injection therapy, electrocoagulation, ligation with a detectable snare, and endoscopic clipping.

###### Perforation

[edit | edit source]

* Perforation rate for ESD is 4.5 percent, compared with 1.0 percent for EMR.[7]
* Tumor location in the upper stomach and size more than 2 cm have been associated with an increased risk of perforation with ESD.
* Treatment of a perforation is endoscopic clipping, open or laparoscopic surgery in case of failed clipping.

### Curative resection

[edit | edit source]

The following criteria need to be fulfilled to consider endoscopic resection curative:[8]

* Enbloc resection
* Tumor size < 2 cm
* Histologically of differentiated type
* Staging of tumor < T1a
* Negative horizontal margin
* Negative vertical margin
* No lymphatic or vascular infiltration

Any resection that does not satisfy any of the above criteria is considered non-curative.

### Management of non-curative resection

[edit | edit source]

* There is no standard approach for managing patients with non-curative resection. Gastrectomy has been recommended especially for tumors associated with a higher risk for lymph node metastases.
* Gastrectomy with removal of perigastric lymph nodes is recommended.[9]
* Seven percent of patients who had gastrectomy and lymph node dissection after non-curative endoscopic resection for early gastric cancer had lymph node metastasis after the procedure.

### Management of positive margins[10]

[edit | edit source]

* Patients with only positive lateral margins can be managed with endoscopic therapy rather than surgery.
* Almost 90 percent of lateral postitve margins were followed endoscopically with no recurrences.
* Patients with positive vertical margins, submucosal invasion, or lymphovascular invasion, are treated by surgery.

### Local recurrence after EMR/ESD

[edit | edit source]

Local mucosal recurrence after EMR/ESD for tumors that had fulfilled the criteria for indication for endoscopic resection may be treated by another ESD.[11]

### Follow-up after endoscopic resection

[edit | edit source]

##### Follow-up after curative resection

[edit | edit source]

* Annual endoscopy with abdominal ultrasonography or CT scan follow-up is recommended.
* Helicobacter pylori should be tested and treated if found.

##### Follow-up after non-curative resection

[edit | edit source]

* Surgical treatment should be performed after non-curative resection such as endoscopic coagulation using a laser or argon-plasma coagulator.

## Surgical Management Of Invasive Gastric Cancer

[edit | edit source]

Surgical management of a gastric tumor with resection of adjacent lymph nodes presents the best chance for long-term survival.

### Types of gastric surgery

[edit | edit source]

#### Curative surgery

[edit | edit source]

* Standard gastrectomy: In the standard gastrectomy, two-thirds of the stomach is resected. It is the principal surgical procedure used.
* Non-standard gastrectomy: In non-standard gastrectomy, the extent of gastric resection and lymphadenectomy is altered according to the stage of tumor.

* Modified surgery: The extent of gastric resection and lymphadenectomy is reduced if compared to standard surgery.

* Extended surgery

* Gastrectomy with resection of adjacent involved organs

* Gastrectomy with extended lymphadenectomy

#### Non-curative surgery

[edit | edit source]

* Palliative surgery: Palliative gastrectomy or gastrojejunostomy is selected depending on the resectability of the primary tumor and surgical risks to relieve symptoms such as bleeding or obstruction.
* Reduction surgery: Reduction surgery aim is to prolong survival by reducing tumor volume.

### Surgeries for gastric cancer

[edit | edit source]

* Total gastrectomy: Total resection of the stomach including the cardia and pylorus
* Distal gastrectomy: Stomach resection including the pylorus. The cardia is preserved
* Pylorus-preserving gastrectomy: Stomach resection preserving the upper third of the stomach and the pylorus with a portion of the antrum
* Proximal gastrectomy: Stomach resection including the cardia. The pylorus is preserved
* Segmental gastrectomy: Circumferential resection of the stomach preserving the cardia and pylorus
* Local resection
* Non-resectional surgery (bypass surgery, gastrostomy, and jejunostomy)

#### Determination of gastric resection

[edit | edit source]

* For T1 tumors, a gross resection margin of 2 cm should be obtained.
* Proximal margin of at least 3 cm is recommended for T2 or deeper tumors with an expansive growth pattern and 5 cm for those with an infiltrative growth pattern.
* For tumors invading the esophagus, a 5-cm margin is not necessarily required, but frozen section examination of the resection line is desirable to ensure a R0 resection.
* When the tumor border is unclear, preoperative endoscopic marking by clips of the tumor border based on biopsy results will be helpful for decision making regarding the resection line.

#### Selection of the surgery[12][13]

[edit | edit source]

* The standard surgical procedure is total or distal gastrectomy.
* Pancreaticosplenectomy
* Pancreatic invasion by tumor requires total gastrectomy regardless of the tumor location.
* Total gastrectomy with splenectomy
* It should be considered for tumors that are located along the greater curvature with metastasis to no. 4 lymph nodes.
* Esophagectomy and proximal gastrectomy
* It should be considered for adenocarcinoma located on the proximal side of the esophagogastric junction.
* Pylorus-preserving gastrectomy
* For tumors in the middle portion of the stomach with the distal tumor border at least 4 cm proximal to the pylorus.

* Vagal nerve preservation
* It is reported that preservation of the hepatic branch of the anterior vagus and the celiac branch of the posterior vagus contributes to improving postoperative quality of life through reducing post-gastrectomy gallstone formation, diarrhea and weight loss. In case of PPG, the hepatic branch should be preserved to maintain the pyloric function.
* Omentectomy
* Removal of the greater omentum is usually integrated into the standard gastrectomy for T3 or deeper tumors.

For T1/T2 tumors, the omentum more than 3 cm away from the gastroepiploic arcade may be preserved.

* Bursectomy[14]
* Bursectomy is removal of the inner peritoneal surface of the bursa omentalis.
* It should be avoided in T1/T2 tumors to prevent injury to the pancreas and adjacent blood vessels.
* There are some survival benefits for bursectomy in T3/T4a tumors.

### Lymph nodes resection

[edit | edit source]

* One of the most controversial areas in the surgical management of gastric cancer is the optimal extent of lymph node dissection.[15]
* The draining lymph nodes for the stomach have been meticulously divided into 16 stations by Japanese surgeons; stations 1 to 6 are perigastric, and the remaining 10 are located adjacent to major vessels, behind the pancreas, and along the aorta.[16]

D1 lymphadenectomy

* It refers to a dissection of only the perigastric lymph nodes.
* A D1 lymphadenectomy is indicated for T1a tumors that do not meet the criteria for EMR/ ESD and for T1bN0 tumors that are histologically of differentiated type and 1.5 cm or smaller in diameter.

D2 lymphadenectomy

* It is an extended lymph node dissection, includes removal of nodes along the hepatic, left gastric, celiac, and splenic arteries, as well as those in the splenic hilum.
* It is indicated for potentially curable T2-T4 tumors.
* A D2 lymphadenectomy should be performed whenever nodal involvement is suspected.

D3 dissection

* It is a superextended lymphadenectomy. The surgery includes D2 lymphadenectomy plus the removal of nodes within the porta hepatis and periaortic regions.[17]

### Local palliative preocedures

[edit | edit source]

* Therapeutic options to control symptoms of local disease progression, such as nausea, pain, bleeding, and obstruction, include palliative surgical resection, surgical bypass (gastrojejunostomy), radiation therapy (RT), and endoscopic techniques.

* Palliative resection
* Palliative gastrectomy should be reserved for extreme, highly symptomatic cases where less invasive methods cannot be used.[18]
* Two-year survival for chemotherapy alone versus gastrectomy plus chemotherapy was 32 versus 25 percent.
* Patients undergoing gastrectomy had a significantly higher incidence of several serious adverse events related to chemotherapy, including leucopenia, nausea, anorexia, and hyponatremia.

* Gastrojejunostomy
* Palliative gastrojejunostomy for gastric outlet obstruction associated with unresectable advanced gastric cancer can improve food intake.[19]
* Palliative gastrojejunostomy for patients with metastatic gastric cancer is reserved for cases where less invasive methods cannot be used.

* Endoscopic stent placement[20][21]
* For palliation of obstructive symptoms, endoscopic placement of a stent provides a less invasive alternative to surgery for symptom palliation and may possibly be more effective in symptom relief.
* Stenting may achieve a better quality of life compared with other forms of palliation.
* In a review of two randomized trials of endoscopic stenting versus palliative gastrojejunostomy, there were no statistically significant differences between the two procedures in terms of efficacy or complications.

* Endoscopic laser therapy[22]
* Laser photocoagulation can be effective, particularly for large tumors with diffuse bleeding.
* An alternative that is being used increasingly is argon plasma coagulation.

### Reconstruction after gastrectomy

[edit | edit source]

Total gastrectomy

* Roux-en-Y esophagojejunostomy[23]
* Jejunal interposition
* Double tract method

Distal gastrectomy

* Billroth I gastroduodenostomy[24]
* Billroth II gastrojejunostomy
* Roux-en-Y gastrojejunostomy
* Jejunal interposition

Pylorus-preserving gastrectomy[25]

* Gastro-gastrostomy
* Proximal gastrectomy
* Esophagogastrostomy
* Jejunal interposition
* Double tract method

## Video shows gastrectomy steps

[edit | edit source]

{{#ev:youtube|5rj7M4kZKp0}}

## Gastric cancer treatment algorithm

[edit | edit source]

| Gastic carcinoma|

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|

| M0|

| M1

| T1|

| T2,T3,T4A|

| T4B|

| N0|

| N1|

| T1a|

| T1b|

| Differenitated,≤1.5cm|

| Differenitated,≤1.5cm|

| Yes|

| No|

| Yes|

| No|

| Endoscopic resection|

| Gastrectomy,D1|

| Gastrectomy,D+1|

| Gastrectomy,D2|

| Gastrectomy,combined resection,D2|

| Chemotherapy,Radiptherapy,Palliative surgery|

## References

[edit | edit source]

1. ↑ Etoh T, Katai H, Fukagawa T, Sano T, Oda I, Gotoda T; et al. (2005). "Treatment of early gastric cancer in the elderly patient: results of EMR and gastrectomy at a national referral center in Japan". Gastrointest Endosc. 62 (6): 868–71. doi:10.1016/j.gie.2005.09.012. PMID 16301028.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
2. ↑ Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; et al. (2016). "Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 27 (suppl 5): v38–v49. doi:10.1093/annonc/mdw350. PMID 27664260.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
3. ↑ Bollschweiler E, Berlth F, Baltin C, Mönig S, Hölscher AH (2014). "Treatment of early gastric cancer in the Western World". World J Gastroenterol. 20 (19): 5672–8. doi:10.3748/wjg.v20.i19.5672. PMC 4024776. PMID 24914327.CS1 maint: Multiple names: authors list (link)
4. ↑ Lee JH, Choi MG, Min BH, Noh JH, Sohn TS, Bae JM; et al. (2012). "Predictive factors for lymph node metastasis in patients with poorly differentiated early gastric cancer". Br J Surg. 99 (12): 1688–92. doi:10.1002/bjs.8934. PMID 23023388.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
5. ↑ Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A; et al. (2015). "Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline". Endoscopy. 47 (9): 829–54. doi:10.1055/s-0034-1392882. PMID 26317585.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
6. ↑ Nishide N, Ono H, Kakushima N, Takizawa K, Tanaka M, Matsubayashi H; et al. (2012). "Clinical outcomes of endoscopic submucosal dissection for early gastric cancer in remnant stomach or gastric tube". Endoscopy. 44 (6): 577–83. doi:10.1055/s-0031-1291712. PMID 22402983.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
7. ↑ Abe Y, Inamori M, Iida H, Endo H, Akiyama T, Yoneda K; et al. (2009). "Clinical characteristics of patients with gastric perforation following endoscopic submucosal resection for gastric cancer". Hepatogastroenterology. 56 (91–92): 921–4. PMID 19621730.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
8. ↑ Japanese Gastric Cancer Association (2017). "Japanese gastric cancer treatment guidelines 2014 (ver. 4)". Gastric Cancer. 20 (1): 1–19. doi:10.1007/s10120-016-0622-4. PMC 5215069. PMID 27342689.
9. ↑ FLY OA, PRIESTLEY JT, COMFORT MW, GAGE RP (May 1958). "Total gastrectomy: mortality and survival". Ann. Surg. 147 (5): 760–8, discussion 768–70. PMC 1450692. PMID 13521695.
10. ↑ Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF (October 2009). "Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy". Ann. Surg. Oncol. 16 (10): 2738–43. doi:10.1245/s10434-009-0616-0. PMID 19636636.
11. ↑ Chaves DM, Maluf Filho F, de Moura EG, Santos ME, Arrais LR, Kawaguti F, Sakai P (April 2010). "Endoscopic submucosal dissection for the treatment of early esophageal and gastric cancer--initial experience of a western center". Clinics (Sao Paulo). 65 (4): 377–82. doi:10.1590/S1807-59322010000400005. PMC 2862673. PMID 20454494.
12. ↑ Kim JY, Ha TK, le Roux CW (2014). "Metabolic effects of gastrectomy with or without omentectomy in gastric cancer". Hepatogastroenterology. 61 (134): 1830–4. PMID 25436387.CS1 maint: Multiple names: authors list (link)
13. ↑ Japanese Gastric Cancer Association (2017). "Japanese gastric cancer treatment guidelines 2014 (ver. 4)". Gastric Cancer. 20 (1): 1–19. doi:10.1007/s10120-016-0622-4. PMC 5215069. PMID 27342689.
14. ↑ Hirao M, Kurokawa Y, Fujita J, Imamura H, Fujiwara Y, Kimura Y; et al. (2015). "Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: Final analysis of a multicenter randomized controlled trial". Surgery. 157 (6): 1099–105. doi:10.1016/j.surg.2014.12.024. PMID 25704429.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
15. ↑ Noguchi Y, Yoshikawa T, Tsuburaya A, Motohashi H, Karpeh MS, Brennan MF (2000). "Is gastric carcinoma different between Japan and the United States?". Cancer. 89 (11): 2237–46. PMID 11147594.CS1 maint: Multiple names: authors list (link)
16. ↑ Japanese Gastric Cancer Association (2011). "Japanese classification of gastric carcinoma: 3rd English edition". Gastric Cancer. 14 (2): 101–12. doi:10.1007/s10120-011-0041-5. PMID 21573743.
17. ↑ Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A; et al. (2008). "D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer". N Engl J Med. 359 (5): 453–62. doi:10.1056/NEJMoa0707035. PMID 18669424.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
18. ↑ Kikuchi S, Arai Y, Kobayashi N, Tsukamoto H, Shimao H, Sakakibara Y; et al. (2000). "Is extended lymphadenectomy valuable in palliatively gastrectomized patients with gastric cancer and simultaneous peritoneal metastasis?". Hepatogastroenterology. 47 (32): 563–6. PMID 10791239.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
19. ↑ Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y; et al. (1998). "Therapeutic significance of palliative operations for gastric cancer for survival and quality of life". J Surg Oncol. 69 (1): 41–4. PMID 9762890.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
20. ↑ Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD (2007). "Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review". BMC Gastroenterol. 7: 18. doi:10.1186/1471-230X-7-18. PMC 1904222. PMID 17559659.CS1 maint: Multiple names: authors list (link)
21. ↑ Wu KL, Tsao WL, Shyu RY (2000). "Low-power laser therapy for gastrointestinal neoplasia". J Gastroenterol. 35 (7): 518–23. PMID 10905359.CS1 maint: Multiple names: authors list (link)
22. ↑ Freitas D, Gouveia H, Sofia C, Cabral JP, Donato A (1995). "Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer". Hepatogastroenterology. 42 (5): 633–7. PMID 8751226.CS1 maint: Multiple names: authors list (link)
23. ↑ Xiao JW, Liu ZL, Ye PC, Luo YJ, Fu ZM, Zou Q; et al. (2015). "Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction". World J Gastroenterol. 21 (34): 9999–10007. doi:10.3748/wjg.v21.i34.9999. PMC 4566393. PMID 26379405.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
24. ↑ Byun C, Cui LH, Son SY, Hur H, Cho YK, Han SU (2016). "Linear-shaped gastroduodenostomy (LSGD): safe and feasible technique of intracorporeal Billroth I anastomosis". Surg Endosc. 30 (10): 4505–14. doi:10.1007/s00464-016-4783-3. PMID 26895918.CS1 maint: Multiple names: authors list (link)
25. ↑ Song P, Lu M, Pu F, Zhang D, Wang B, Zhao Q (2014). "Meta-analysis of pylorus-preserving gastrectomy for middle-third early gastric cancer". J Laparoendosc Adv Surg Tech A. 24 (10): 718–27. doi:10.1089/lap.2014.0123. PMID 25243417.CS1 maint: Multiple names: authors list (link)

Template:WH Template:WS